Elysium Therapeutics is a biotech company focusing on safer medicines and overdose prevention. It develops SMART products designed to outlast potent synthetic opioids like fentanyl and reduce adverse events, including opioid overdoses. Its portfolio includes SOOPR Naloxone, a long-acting rescue agent for fentanyl-related overdoses, and O2P Oral Overdose Protection, a self-limiting opioid delivery system to reduce misuse and overdose. The company emphasizes addressing the opioid crisis with innovative countermeasures aimed at improving public health safety, particularly in the United States.